Edwards Lifesciences (NYSE:EW) updated its second quarter 2019 earnings guidance on Tuesday. The company provided earnings per share guidance of $1.27-1.37 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $1.33. The company issued revenue guidance of $1.02-1.08 billion, compared to the consensus revenue estimate of $1.04 billion.Edwards Lifesciences also updated its FY 2019 guidance to $5.10-5.35 EPS.
Several research analysts have recently weighed in on the stock. BTIG Research restated a hold rating on shares of Edwards Lifesciences in a research note on Wednesday. Raymond James lowered their price objective on shares of Edwards Lifesciences from $210.00 to $200.00 and set an outperform rating on the stock in a research note on Wednesday. Jefferies Financial Group lifted their target price on shares of Edwards Lifesciences from $195.00 to $210.00 and gave the stock a buy rating in a report on Wednesday. Deutsche Bank lifted their target price on shares of Edwards Lifesciences from $164.00 to $184.00 and gave the stock a hold rating in a report on Wednesday. Finally, Credit Suisse Group lifted their target price on shares of Edwards Lifesciences from $189.00 to $221.00 and gave the stock an outperform rating in a report on Monday, April 15th. Two analysts have rated the stock with a sell rating, eight have given a hold rating and thirteen have issued a buy rating to the stock. The stock currently has an average rating of Hold and a consensus price target of $185.86.
Shares of EW stock traded down $1.78 during midday trading on Wednesday, hitting $179.20. 1,104,169 shares of the company were exchanged, compared to its average volume of 1,325,963. The company has a market capitalization of $36.88 billion, a price-to-earnings ratio of 38.13, a PEG ratio of 2.31 and a beta of 0.91. The company has a debt-to-equity ratio of 0.19, a quick ratio of 1.92 and a current ratio of 2.61. Edwards Lifesciences has a 52 week low of $123.00 and a 52 week high of $197.86.
In other Edwards Lifesciences news, CEO Michael A. Mussallem sold 32,800 shares of the business’s stock in a transaction dated Tuesday, February 12th. The shares were sold at an average price of $176.90, for a total value of $5,802,320.00. Following the completion of the sale, the chief executive officer now owns 75,926 shares of the company’s stock, valued at approximately $13,431,309.40. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, VP Catherine M. Szyman sold 1,474 shares of the business’s stock in a transaction dated Monday, April 15th. The shares were sold at an average price of $192.00, for a total transaction of $283,008.00. Following the completion of the sale, the vice president now directly owns 21,132 shares of the company’s stock, valued at approximately $4,057,344. The disclosure for this sale can be found here. Insiders sold a total of 114,328 shares of company stock valued at $20,121,304 in the last three months. Insiders own 1.63% of the company’s stock.
TRADEMARK VIOLATION NOTICE: This news story was reported by Baseball Daily News and is the property of of Baseball Daily News. If you are reading this news story on another publication, it was illegally stolen and republished in violation of United States & international copyright & trademark law. The correct version of this news story can be viewed at https://www.baseballdailydigest.com/news/2019/04/24/edwards-lifesciences-ew-releases-q2-2019-earnings-guidance.html.
About Edwards Lifesciences
Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States and internationally. It offers transcatheter heart valve therapy products comprising transcatheter aortic valve replacement, and transcatheter mitral and tricuspid therapies for the nonsurgical replacement of heart valves.
Read More: What are different types of coverage ratios?
Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.